First Wave BioPharma, Inc.’s interview, Mr. James Sapirstein, Chairman, CEO & President.

0
203

Mr. James Sapirstein, Chief Executive Officer at First Wave BioPharma, Inc. (NASDAQ: FWBI) (formerly known as AzurRX Biopharma, Inc.), a clinical-stage biopharmaceutical Company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Mr. Sapirstein provides TV Anchor Jane King with a comprehensive update on current clinical trials in the USA and Europe. With 150+ people enrolled in a clinical trial on the gastrointestinal problems related to COVID-19, the Company expects in about 45-days those results on FW-COV. James talks about the current “Blind” trial ongoing in Italy, a study on ulcerated proctitis. This study uses the Company’s drug, FW-UP (niclosamide), preliminary data expected sometime in the 2nd quarter, 2022. Adrulipase, the Company’s drug used in several studies over the last seven years, James talks about the drug’s 2- trials performed in 2021, resulting in mixed results. He believes the reformulation of the adrulipase compound could provide targeted results and expects to release preliminary data sometime during the second half of 2022. James looks forward to a rebound in the biotech industry and feels that FWBI is in a position for success throughout 2022.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet

Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/

Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet

About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list